Healthcare / Medical Instruments & SuppliesTokyo
$830.00
+1.00 (+0.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $300.7M · quality 37.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18.5B
P/E
13.6x
↓EV/EBITDA
5.3x
↓ROE
6.7%
↑Gross Margin
11.9%
↓Debt/Equity
1.04
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.4%
FCF CAGR
—
FCF margin
1.7%
FCF / Net income
3.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $288.69B · net income $1.38B · FCF $4.95B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $288.69B | $288.69B | $259.79B | $239.05B | $226.61B |
| Net Income | $1.38B | $1.38B | $1.12B | $1.50B | $1.87B |
| EBITDA | $4.77B | $4.77B | $3.86B | $4.27B | $3.80B |
| EPS | 61.85 | 61.85 | 51.00 | 68.09 | 85.15 |
| Gross Margin | 11.9% | 11.9% | 12.0% | 12.3% | 12.1% |
| Operating Margin | 0.6% | 0.6% | 0.5% | 0.8% | 1.0% |
| Net Margin | 0.5% | 0.5% | 0.4% | 0.6% | 0.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.04 | 1.04 | 1.22 | 1.05 | 1.03 |
| Current Ratio | 1.09 | 1.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.95B | $4.95B | $261.1M | $300.7M | $-8.49B |
| Returns | |||||
| ROE | 6.7% | 6.7% | 5.7% | 8.1% | 10.8% |
| Valuation | |||||
| P/E | 13.62 | 13.62 | 17.47 | 11.57 | 11.29 |
| EV/EBITDA | 5.32 | 5.32 | 7.78 | 6.22 | 7.84 |
| P/B | 0.90 | 0.90 | 0.99 | 0.93 | 1.22 |
| Growth & Yield | |||||
| Revenue Growth | 11.1% | 11.1% | 8.7% | 5.5% | — |
| EPS Growth | 21.3% | 21.3% | -25.1% | -20.0% | — |
| Dividend Yield | 2.4% | 2.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.0%
EPS terminal req.
$73.65
Spread vs growth
15.3%
5Y implied EPS CAGR
7.6%
EPS terminal req.
$89.11
Spread vs growth
13.7%
10Y implied EPS CAGR
8.8%
EPS terminal req.
$143.52
Spread vs growth
12.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.8%
Start / end P/E
19.0x → 13.4x
EPS bridge
51.00 → 61.85
Residual
-6.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.